Published in J Card Fail on December 03, 2011
The Cardio-Oncology Breast Cancer Study (COBC) | NCT02571894
Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol (2013) 1.89
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci (2012) 1.08
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf (2014) 0.98
Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol (2015) 0.95
Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist (2013) 0.89
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat (2012) 0.88
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction. Oncologist (2015) 0.85
Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat (2014) 0.82
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics (2013) 0.82
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat (2015) 0.80
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) (2015) 0.78
Mild hyperthermia influence on Herceptin(®) properties. Radiol Oncol (2015) 0.77
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Hum Vaccin Immunother (2016) 0.76
Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience. Breast Care (Basel) (2014) 0.75
Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist (2016) 0.75
Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study. Cancer (2015) 0.75
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes. Clin Transl Med (2017) 0.75
Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting. Med Oncol (2017) 0.75
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging (2009) 1.89
Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart (2010) 1.80
Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy. Eur J Heart Fail (2013) 1.48
Alternative splicing and nonsense-mediated mRNA decay regulate mammalian ribosomal gene expression. Nucleic Acids Res (2005) 1.48
Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med (2012) 1.48
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther (2010) 1.43
Chronobiological patterns of onset of Tako-Tsubo cardiomyopathy: a multicenter Italian study. J Am Coll Cardiol (2009) 1.42
[Clinical competence certification for advanced heart failure: an emerging need also in Italy?]. G Ital Cardiol (Rome) (2015) 1.40
Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol (2002) 1.29
Unusual left atrial appendage thrombus in a neonate with normal heart after sustained supraventricular tachycardia. Int J Cardiol (2007) 1.26
The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation (2007) 1.18
Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol (2003) 1.13
Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension (2003) 1.07
Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. J Cardiovasc Med (Hagerstown) (2010) 1.03
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. J Thorac Oncol (2015) 1.01
cis-acting sequences and trans-acting factors in the localization of mRNA for mitochondrial ribosomal proteins. Biochim Biophys Acta (2008) 1.00
Human rpL3 induces G₁/S arrest or apoptosis by modulating p21 (waf1/cip1) levels in a p53-independent manner. Cell Cycle (2012) 0.98
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer (2007) 0.97
hnRNP H1 and intronic G runs in the splicing control of the human rpL3 gene. Biochim Biophys Acta (2010) 0.97
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat (2012) 0.96
Autoregulatory circuit of human rpL3 expression requires hnRNP H1, NPM and KHSRP. Nucleic Acids Res (2011) 0.95
The 3'-untranslated region directs ribosomal protein-encoding mRNAs to specific cytoplasmic regions. Biochim Biophys Acta (2006) 0.95
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer (2009) 0.93
Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Prev Cardiol (2011) 0.92
Mitral and aortic valve sclerosis/calcification and carotid atherosclerosis: results from 1065 patients. Heart Vessels (2013) 0.91
Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur J Cardiovasc Prev Rehabil (2011) 0.91
Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. J Exp Clin Cancer Res (2013) 0.91
Absence of inferior vena cava as a rare cause of deep venous thrombosis complicated by liver and lung embolism. Int J Cardiol (2003) 0.90
Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) (2010) 0.90
Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care (2012) 0.90
A facility to search for hidden particles at the CERN SPS: the SHiP physics case. Rep Prog Phys (2016) 0.90
Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial). Cardiovasc Ultrasound (2012) 0.89
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail (2012) 0.89
Cardiac toxicity in cancer survivors. Cancer (2013) 0.89
Modulations of autonomic activity leading to tilt-mediated syncope. Int J Cardiol (2006) 0.89
Clinical characteristics and outcome of left ventricular ballooning syndrome in a European population. Am J Cardiol (2011) 0.88
The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. Eur J Cardiothorac Surg (2007) 0.88
Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5. Br J Pharmacol (2005) 0.88
Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). Tumori (2011) 0.88
Discovery of a novel small molecule inhibitor targeting the frataxin/ubiquitin interaction via structure-based virtual screening and bioassays. J Med Chem (2013) 0.87
Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J (2005) 0.87
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opin Pharmacother (2013) 0.86
Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med (Hagerstown) (2014) 0.85
Autonomic profile and arrhythmic risk stratification after surgical repair of tetralogy of Fallot. Am Heart J (2004) 0.85
Translation and validation of the Italian version of the European Heart Failure Self-care Behaviour Scale. J Cardiovasc Med (Hagerstown) (2010) 0.85
Physical and emotional symptom burden of patients with end-stage heart failure: what to measure, how and why. J Cardiovasc Med (Hagerstown) (2008) 0.85
Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod Biol (2005) 0.85
Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile. Pathol Res Pract (2006) 0.85
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat (2011) 0.84
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol (2007) 0.84
Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J Mol Med (Berl) (2007) 0.84
Impact of aortic or mitral valve sclerosis and calcification on cardiovascular events and mortality: a meta-analysis. Int J Cardiol (2013) 0.84
Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist (2012) 0.84
The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract (2013) 0.84
Dynamic mild subaortic left ventricular obstruction caused by an accessory mitral valve attached to the anterior mitral valve in a young pregnant woman. Eur J Echocardiogr (2008) 0.84
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. J Cardiovasc Med (Hagerstown) (2007) 0.84
Six-minute walking test after cardiac surgery: instructions for an appropriate use. Eur J Cardiovasc Prev Rehabil (2009) 0.83
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). BMC Cancer (2014) 0.83
Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail (2009) 0.83
Analysis of circumferential and longitudinal left ventricular systolic function in patients with non-ischemic chronic heart failure and preserved ejection fraction (from the CARRY-IN-HFpEF study). Am J Cardiol (2011) 0.83
The inability to perform a 6 minute walking test after cardio-thoracic surgery is a marker of clinical severity and poor outcome. Data from the ISYDE-2008 Italian survey. Int J Cardiol (2011) 0.83
Left atrial work in patients with stable chronic heart failure: factors associated and prognostic role. Echocardiography (2013) 0.83
The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail (2013) 0.82
Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. Diabetes Res Clin Pract (2013) 0.82
A difficult diagnosis: right unilateral cardiogenic pulmonary edema. Usefulness of biochemical markers of heart failure for the correct diagnosis. Ital Heart J (2005) 0.82
Coronary-to-bronchial anastomosis: an unusual cause of hemoptysis. J Cardiovasc Med (Hagerstown) (2007) 0.81
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Clin Breast Cancer (2005) 0.81
Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown) (2009) 0.81
Circadian rhythms, adrenergic hormones and trafficking of hematopoietic stem cells. Expert Opin Ther Targets (2010) 0.81
Prevalence of undiagnosed asymptomatic aortic valve stenosis in the general population older than 65 years. A screening strategy using cardiac auscultation followed by Doppler-echocardiography. Int J Cardiol (2013) 0.81
Relationships of the appropriateness of left ventricular mass to left atrial size and function in arterial hypertension. J Cardiovasc Med (Hagerstown) (2007) 0.80
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. Protein Eng Des Sel (2014) 0.80
Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. J Cardiovasc Med (Hagerstown) (2014) 0.80
Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol (2008) 0.80
Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study. Eur J Heart Fail (2006) 0.80
Thrombus or tumor? a case of fibroelastoma as indicated during the submission process. Cases J (2009) 0.80